April 2014

Did you know? Women are 37% more likely to have COPD than men. Once considered a “man’s disease” COPD is now far more prevalent in women. On the blog this month, we take a closer look at why women are more commonly affected. Keep reading to learn more.

Lastly, are you sleeping well? Approximately 50 percent of COPD patients report significant sleep disturbances. If you fall in this category, it’s important to speak to your doctor! Check out our 7 tips to help you get a restful night’s sleep.

Have you been treated at Lung Institute and would like to share your treatment story? We would love to feature you in our next edition.
Contact us at info@lunginstitute.com.


COPD in Women

You may be surprised to hear that COPD is more common in women. In fact, women are 37% more likely to have COPD than men. Women also account for more than half of all deaths attributed to COPD in the United States. Women are at a higher risk for COPD than men.

COPD was once considered a “man’s disease.” It seemed like it struck older, white men more than any other group. American soldiers were given cigarettes in their rations for years, and well-known images of the Marlboro Man reinforced the link between men and smoking.

Read more

7 Things You Need to Know about Sleep  and COPD

If you have COPD, you know that difficulty breathing isn’t just limited to the daytime and often gets in the way of falling asleep. This can lead to mild fatigue and in severe cases debilitating exhaustion. People with COPD are more likely to develop insomnia, nightmares, and daytime sleepiness when compared to the general population. Approximately 50 percent of COPD patients report significant sleep disturbances. If you fall in this category it’s important to address your sleep disturbance immediately.

Read more

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.